Hostname: page-component-78c5997874-8bhkd Total loading time: 0 Render date: 2024-11-14T23:14:43.792Z Has data issue: false hasContentIssue false

Outcomes of Neutropenic Patients with Clostridium difficile Infection

Published online by Cambridge University Press:  02 November 2020

Roopali Sharma
Affiliation:
Touro College of Pharmacy
Deepali Dixit
Affiliation:
Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey
Sherin Pathickal
Affiliation:
Wyckoff Heights Medical Center, Brooklyn, NY
Jenny Park
Affiliation:
Allergan
Bernice Lee
Affiliation:
Rutgers, The State University of New Jersey
Siddharth Jain
Affiliation:
Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey
Joelle Kairys
Affiliation:
Touro College of Pharmacy
Nino Katchiuri
Affiliation:
Touro College of Pharmacy
Tae Park
Affiliation:
Bronxcare Health System
Navneeth Narayanan
Affiliation:
Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey
Siddharth Swamy
Affiliation:
Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Background: Data from Clostridium difficile infection (CDI) in neutropenic patients are still scarce. Objective: To assess outcomes of CDI in patients with and without neutropenia. Methods: The study included a retrospective cohort of adult patients at 3 academic hospitals between January 2013 and December 2017. The 2 study arms were neutropenic patients (neutrophil count <500/mm3) and nonneutropenic patients with confirmed CDI episodes. The primary outcome evaluated the composite end point of all-cause in-hospital mortality, intensive care unit (ICU) admissions, and treatment failure at 7 days. The secondary outcome evaluated hospital length of stay. Results: Of 962 unique cases of CDI, 158 were neutropenic (59% men) and 804 were nonneutropenic (46% men). The median age was 57 years (IQR, 44–64) in the neutropenic group and 68 years (IQR, 56–79) in the nonneutropenic group. The median Charlson comorbidity score was 5 (IQR, 3–7.8) and 4 (IQR, 3–5) in the neutropenic and nonneutropenic groups, respectively. Regarding severity, 88.6% versus 48.9% were nonsevere, 8.2% versus 47% were severe, and 3.2% versus 4.1% were fulminant in the neutropenic and nonneutropenic groups, respectively. Also, 63% of patients (60.9% in nonneutropenic, 65.2% in neutropenic) were exposed to proton-pump inhibitors. A combination CDI treatment was required in 53.2% of neutropenic patients and 50.1% of nonneutropenic patients. The primary composite end point occurred in 27% of neutropenic patients versus 22% of nonneutropenic patients (P = .257), with an adjusted odds ratio of 1.30 (95% CI, 0.84–2.00). The median hospital length of stay after controlling for covariates was 21.3 days versus 14.2 days in the neutropenic and nonneutropenic groups, respectively (P < .001). Complications (defined as hypotension requiring vasopressors, ileus, or bowel perforation) were seen in 6.0% of the nonneutropenic group and 4.4% of the neutropenic group (P = .574), with an adjusted odds ratio of 0.61 (95% CI, 0.28–1.45). Conclusions: Neutropenic patients were younger and their cases were less severe; however, they had lower incidences of all-cause in-hospital mortality, ICU admissions, and treatment failure. Hospital length of stay was significantly shorter in the neutropenic group than in the nonneutropenic group.

Funding: None

Disclosures: None

Type
Poster Presentations
Copyright
© 2020 by The Society for Healthcare Epidemiology of America. All rights reserved.